Chinese Scientists Develop Novel Cancer Therapy Using Reprogrammed Mast Cells to Convert "Cold" Tumors into "Hot" Targets
Key Insights
Chinese researchers from Zhejiang University (search) have successfully reprogrammed mast cells (search) using IgE antibodies (search) to trigger allergy-like immune responses specifically within tumors, converting immunologically "cold" tumors into "hot" ones that can be recognized and attacked by the immune system.
The innovative approach demonstrated effectiveness in mouse models of melanoma (search), breast cancer (search), and lung metastasis (search), as well as in patient-derived tumor models targeting HER2 (search)-positive cancers, showing enhanced T-cell infiltration and significant tumor growth inhibition.
Beyond serving as delivery vehicles for oncolytic viruses, the mast cell platform can potentially carry diverse therapeutic payloads including drugs, proteins, antibodies, and nanomedicines, opening possibilities for personalized precision cancer (search) therapy.
Scientists from Zhejiang University (search) and the First Hospital of China Medical University (search) have developed a groundbreaking cancer (search) therapy that harnesses the body's allergic response mechanism to fight tumors. The research, published in Cell on Wednesday, demonstrates how reprogrammed mast cells (search) can transform immunologically "cold" tumors into "hot" targets that the immune system can effectively attack.
Reprogramming Allergic Response for Cancer Treatment
The innovative approach centers on mast cells (search), immune cells typically responsible for triggering allergic symptoms such as hives and sneezing. These cells are naturally loaded with inflammatory molecules and can react within seconds when activated. Professor Gu Zhen from the School of Pharmacy at Zhejiang University (search), who led the research team, explained that the overactive immune response inspired the team to explore whether inducing allergic-type reactions in tumors could help overcome tumor immunosuppression.
The researchers reprogrammed mast cells (search) using IgE antibodies (search) that specifically recognize proteins found on tumor cells, rather than allowing them to respond to traditional allergens. When these customized mast cells are injected into the bloodstream, they travel to tumors and unleash sudden bursts of inflammation upon encountering their specific cancer (search) targets.
Converting Cold Tumors to Hot Targets
The allergy-like reaction inside the tumor helps activate the immune system and converts quiet, hard-to-treat "cold" tumors, which typically evade immune detection, into "hot" ones that immune cells can recognize and attack. This transformation is crucial for cancer (search) immunotherapy success, as cold tumors often resist current treatment approaches.
The researchers discovered that mast cells (search) can also serve as living carriers for oncolytic viruses—specialized viruses that selectively infect and kill cancer (search) cells. By hiding these viruses inside mast cell vesicles, the team protected them from destruction in the bloodstream. Once the mast cells reached a tumor and became activated, the viruses were released directly at the target site.
Promising Preclinical Results
In mouse models of melanoma (search), breast cancer (search), and lung metastasis (search), the approach successfully drew more cancer (search)-killing T cells into tumors and inhibited tumor growth. The strategy also demonstrated effectiveness in patient-derived tumor models, where human mast cells (search) equipped with IgE antibodies (search) targeting the common tumor marker HER2 (search) and loaded with oncolytic viruses triggered strong T-cell responses and notable tumor suppression.
"This opens up possibilities for precision therapy in the future," Gu said, noting that matching IgE antibodies (search) to a patient's own cancer (search) markers could rapidly create personalized therapy approaches.
Versatile Therapeutic Platform
Beyond oncolytic viruses, mast cells (search) can carry a wide range of therapeutic payloads, including drugs, proteins, antibodies, and nanomedicines, releasing them only when they encounter tumor tissue. The researchers indicated that this platform could eventually support multiple treatment modes within a single cell-based therapy, offering unprecedented therapeutic flexibility.
Path to Clinical Translation
The research team has outlined plans to advance their approach toward clinical application. They aim to establish a workflow for selecting patient-specific IgE antibodies (search), scale up manufacturing of therapeutic mast cells (search), and explore combinations with existing cancer (search) immunotherapies. Gu emphasized the team's commitment to bringing their approach to clinical application as soon as possible.